Key Highlights
- AI Proteins partners with Bristol Myers Squibb to develop novel miniprotein-based therapies.
- Collaboration includes an upfront payment and milestone payments valued up to $400M plus royalties.
- AI-driven miniproteins offer high affinity, small size, and therapeutic advantages.
- Bristol Myers Squibb gains exclusive worldwide licensing options for multiple targets.
Source: Business Wire
Notable Quote
- “We are excited to partner with Bristol Myers Squibb to bring our cutting-edge protein design technology to the clinic. By combining our expertise in protein engineering with Bristol Myers Squibb’s deep knowledge of pharmaceutical development, we aim to create a new generation of targeted therapies that can transform patient outcomes.” — Chris Bahl, PhD, President, CSO and Founder at AI Proteins
SoHC's Take
This collaboration exemplifies the growing synergy between artificial intelligence and biotechnology, heralding a new era in therapeutic development. AI Proteins’ innovative platform underscores the potential of AI in designing highly specific and effective protein-based therapeutics, challenging traditional paradigms. Partnering with a pharmaceutical powerhouse like Bristol Myers Squibb not only validates AI Proteins’ technology but also accelerates the potential for real-world impact in transforming patient outcomes across multiple therapeutic areas. This collaboration is a significant milestone in the evolution of AI-driven drug discovery.
